Rahul R. Nagawade, PhD has joined Devsynthesis India Pvt. Ltd. as Chief Scientific Officer, bringing with him an exceptional blend of scientific depth, leadership, and nearly 27 years of experience in drug discovery and medicinal chemistry. With a strong academic foundation—including a Master’s degree in Drug Chemistry and a PhD in Chemistry from India—Rahul’s appointment marks a significant step in strengthening Devsynthesis’ scientific vision and innovation agenda.
Over the course of his distinguished career, Rahul has built deep expertise in synthetic and medicinal chemistry, spanning novel phosphorus-based peptide coupling reagents, synthesis of New Chemical Entities (NCEs), and development of innovative synthetic methodologies. His work has covered diverse therapeutic areas, with particular strength in anti-infectives, oncology, antivirals, metabolic disorders, and inflammation, across chemical classes such as pyridazines, dihydropyrimidones, quinazolines, quinolines, and more.
Prior to joining Devsynthesis in February 2026, Rahul spent 18 impactful years at Sai Life Sciences Ltd., most recently as AVP & Delivery Head – Discovery Chemistry. During this tenure, he played a pivotal role in supporting biotech companies, mid-sized pharmas, and global pharmaceutical majors across the US and Europe—largely through long-term FTE collaborations. His contributions spanned the full drug discovery lifecycle, from concept to clinic, working closely with DMPK, biology, PRD, formulation, and particle science teams, with a strong execution focus on chemistry. His portfolio includes multiple compounds in clinical development, notably in oncology (including Tazemetostat), antifungal, and antiviral programs, with several others nearing nomination.
Earlier in his career, Rahul contributed to global discovery programs at TCG Life Sciences (Chembiotek) and Wockhardt, where he worked extensively on anti-infective research involving cephalosporins, fluoroquinolones, oxazolidinones, macrolides, and ketolides. A well-published scientist, his research has appeared in leading journals such as European Journal of Medicinal Chemistry, Tetrahedron Letters, Bioorganic & Medicinal Chemistry Letters, and others. As CSO at Devsynthesis, Rahul is poised to drive scientific excellence, deepen client partnerships, and accelerate the translation of innovative chemistry into meaningful therapeutic outcomes.